-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-289 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-289 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-289 in Solid Tumor Drug Details:IOA-289 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Natural Killer Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Natural Killer Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Natural Killer Cell Lymphomas Drug Details:IOA-244 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Peripheral T-Cell Lymphomas (PTCL) Drug Details:IOA-244 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Non-Small Cell Lung Cancer Drug Details:IOA-244 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)Drug Details:IOA-244 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Anaplastic Large Cell Lymphoma (ALCL) Drug Details:IOA-244 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:IOA-244 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic LymphadenopathyDrug Details:IOA-244 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taladegib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Taladegib in Solid Tumor Drug Details: Taladegib (LY-2940680) is under development for the treatment of...